Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

About this update from Vortex Energy Corp.

[{"type":"text","content":"Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings\n\n\n .bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }\n \n\n\n\n Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT.\n \n\n “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Building on this momentum, we are focused on expanding our commercial reach in multiple disease areas; advancing the emerging renal franchise, including the potential near-term launch of povetacicept; and progressing our mid- and late-stage clinical pipeline. Vertex is well positioned to serve many more patients with our expanding portfolio of transformative medicines, and in so doing, deliver sustained growth and long-term value for shareholders.”\n \n\n\n\n Disease Areas with Approved Medicines\n \n\n\n\n\n Cystic Fibrosis (CF)\n \n\n\n\n\n ALYFTREK\n \n ®\n \n :\n \n ALYFTREK is now approved in the U.S., the United Kingdom (U.K.), the European Union (EU), Canada, New Zealand, Switzerland, and Australia for people with CF 6 years and older who have at least one F508del mutation or another mutation in the\n \n cystic fibrosis transmembrane conductance regulator (CFTR)\n \n gene that is responsive to ALYFTREK. Eligible patients in the U.S., England, Ireland, Germany, Denmark, Northern Ireland, Norway, and Wales currently have reimbursed access to ALYFTREK, and Vertex is working to secure access for eligible patients in additional countries. Vertex plans to share data from the global study of ALYFTREK in children 2 to 5 years of age and submit to global regulators in 2026. Vertex expects to initiate a pivotal study of ALYFTREK in children 1 to 2 years of age in 2026.\n \n\n\n TRIKAFTA\n \n ®\n \n :\n \n Following positive results from the study of TRIKAFTA in patients one year to less than two years of age, reported in November 2025, Vertex expects to submit for approv...

More updates from Vortex Energy Corp.